Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 92,689

Document Document Title
WO/2019/014464A1
The present technology relates generally to the generation of induced pluripotent stem cells (iPSCs). In particular aspects, the present technology relates generally to methods for generating iPSCs from non-pluripotent cells, such as age...  
WO/2019/014518A1
The present invention relates to a method of preventing or reducing dermatological side effects of the therapeutic agents in a subject without substantial loss in efficacy, where the therapeutic agents would otherwise have significant ef...  
WO/2019/012030A1
The present invention relates to the field of cancer treatment. In this study, the inventors sought to investigate whether this antiproliferative effect of DHODH inhibitors could be enhanced by combining Chk1 kinase inhibition. They show...  
WO/2019/013607A1
The present invention relates to a composition for inhibiting octamer-binding transcription factor 4 (OCT4) and a use thereof. Specifically, the present invention relates to a composition for removing undifferentiated cells or inhibiting...  
WO/2019/008393A1
This invention relates to a new use of compounds that are angiotensin II (Ang II) receptor agonists, more particularly agonists of the Ang II type 2 receptor (the AT2 receptor), and especially agonists that bind selectively to the AT2 re...  
WO/2019/009265A1
The present invention addresses the problem of providing a medicine with which it is possible to simply treat and/or prevent retinal degenerative diseases associated with photoreceptor degeneration, including retinitis pigmentosa. The so...  
WO/2019/010255A1
Provided herein are methods and compositions related to Bifidobacterium animalis ssp. lactis useful as therapeutic agents.  
WO/2019/008239A1
The invention relates to the use of imeglimin for preventing and/or treating hepatocellular carcinoma.  
WO/2019/007368A1
Disclosed are a drug containing isovalerylspiramycin I, II and/or III, and the use of isovalerylspiramycin I, II and/or III in the preparation of a drug for treating and/or preventing a tumour.  
WO/2019/010314A1
The present invention relates in one aspect to the discovery that β-Klotho is the primary cell-surface receptor for FGF21, with FGFR1c functioning as a catalytic subunit that ultimately mediates intracellular signaling. In one aspect, t...  
WO/2019/009436A1
The present invention relates to: a compound in which a carbonyl group in serine is linked by peptide bonding or ester bonding to a terminal group in a polymeric carrier having multiple terminal groups directly or through a linker; a dru...  
WO/2019/008408A1
Myeloproliferative neoplasms (MPNs) are acquired clonal hematopoietic stem cell disorders, characterized by an increase in one or more myeloid lineages. More than 90% of patients with PV and half of those with ET and PMF carry a mutation...  
WO/2019/009434A1
The present invention relates to: a compound that is formed by linking the α carbonyl group of aspartic acid directly or via a linker to at least 50% of all of the terminal groups of a dendritic polymer that has a plurality of terminal ...  
WO/2019/010465A1
The present invention relates to antimicrobial, disinfecting, and wound healing compositions and methods for producing and using the same. The compositions may comprise one or more of a peracid, a hydroperoxide, a bis(hydroperoxide), or ...  
WO/2019/008485A1
This present invention relates to pharmaceutical composition comprising fixed dose combination of valsartan or pharmaceutically acceptable salts thereof and sacubitril or pharmaceutically acceptable salts thereof. Further this invention ...  
WO/2019/010092A1
Compositions comprising Compound I of the formula (I) and methods of treating cystic fibrosis comprising administering Compound I. Compositions comprising a pharmaceutically acceptable salt of Compound I and methods of treating cystic fi...  
WO/2019/007996A1
Metal complexes comprising a compound of general formula (I) and at least one metal ion, for use in the treatment of diseases related to the accumulation of intracellular deposits and/or diseases related to defective autophagy and/or def...  
WO/2019/004292A1
Provided are a medicine for preventing or treating chronic pain and a method for preventing or treating chronic pain. A medicinal composition comprising a serotonin-3 receptor agonist, for example, a compound represented by formula (I) [...  
WO/2019/000605A1
The present invention relates to a method for inhibiting myopia and an application in preparing a drug. By inhibiting HIF-1α expression in eyes, anti-hypoxic effect is achieved, thereby inhibiting myopia. By inhibiting the functions of ...  
WO/2019/006003A1
The present invention provides, in some embodiments, methods of promoting an immune response in a subject in need thereof, comprising administering to a subject a population of immune cells that express an exogenous enzyme that facilitat...  
WO/2019/005643A1
A topical composition can be used to treat or inhibit onset of fibrillar collagenous growths, including but not limited to keloids. The composition includes elemental iodine carried in a non-migratory vehicle. Application of the composit...  
WO/2019/002473A1
The present invention provides a composition for treating acute urinary retention and reducing the recurrences rates in a male patient by administering a composition for treating acute urinary retention, said composition comprises at lea...  
WO/2019/005754A1
Provided herein are compositions, systems, kits, and methods for treating cancer by administering to a subject an agent that inhibits a target mRNA or target protein selected from ROR2, JNK1, LCK, LIME, BRCA1, and MLH1. In certain embodi...  
WO/2019/004088A1
The present invention addresses the problem of providing a mucoadhesive oral preparation which shows a high drug absorption rate and a high drug release speed. As a means for solving this problem, provided is a mucoadhesive oral preparat...  
WO/2019/005756A1
The present disclosure provides antibody-drug conjugates comprising (i) antibodies that specifically bind to Mer Tyrosine Kinase (MERTK) (e.g., human MERTK, or both human and mouse MERTK), and (ii) cytotoxic agents conjugated directly to...  
WO/2019/006050A1
The present invention describes the combination of a NK1-antagonist with pramipexole or a pharmaceutically acceptable salt or solvate thereof, useful for treating depressive disorders, including major depressive disorder.  
WO/2019/004464A1
The purpose of the present invention is to provide a composition for inhibiting the proliferation and/or infiltration of tumor cells, an enhancer of an anti-tumor effect of a drug for the purpose of removing immunosuppression associated ...  
WO/2019/004338A1
This pharmaceutical composition comprises biocompatible particles containing a sugar derivative, wherein the biocompatible particles comprise a lactic acid/glycolic acid copolymer. The pharmaceutical composition may be used in combinatio...  
WO/2019/004417A1
Provided are a novel method for treating cancer, said method exhibiting a remarkably excellent antitumor effect with little side effect, and an immunostimulant. An antitumor agent and an immunostimulant, characterized by comprising an az...  
WO/2019/004419A1
The present inventors found that postoperative cancer recurrence and/or metastasis were inhibited by administering a β blocker to a cancer patient in the perioperative period. Thus, the present disclosure provides an inhibitor of postop...  
WO/2019/004466A1
Provided is a medicine for safely treating a patient who needs to be treated with the use of pemafibrate, a salt thereof or a solvate of the same (hereinafter called "pemafibrate treatment"). The medicine for treating a patient who needs...  
WO/2019/002068A1
The present invention relates to : • combinations of : * a component A : which is a PI3K kinase inhibitor, such as copanlisib, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiolo...  
WO/2019/004825A1
The invention relates to the fields of medicine and virology, more in particular to means and methods for treating a viral disease caused by flaviviruses or alphaviruses. Provided is tomatidine or an analog thereof for use in a method of...  
WO/2019/004642A1
Disclosed is an oral dissolving film for a pet. The oral dissolving film for a pet according to the present invention comprises a base layer and an outer coating layer stacked on a surface of the base layer, the base layer comprising at ...  
WO/2019/002858A1
The present invention relates to compositions, in particular dietary compositions,that comprise a combination of choline cation and succinate anion (2-) and nicotinamide, and use of these compositions for maintaining and enhancing the br...  
WO/2018/234811A1
The present invention relates to the use of cannabidiol (CBD) for the treatment of tumours associated with Tuberous Sclerosis Complex (TSC). In particular the CBD was able to decrease the number and size of marker cells, pS6, in a zebraf...  
WO/2018/236928A1
The invention provides novel classes of HCV therapeutics that are orally available, safe and effective HCV NS3/4A protease inhibitors and are less susceptible to drug resistance than existing therapeutics. The invention also relates to p...  
WO/2018/235935A1
Provided is a medicinal composition containing a water-soluble thickening agent, wherein a decrease in the viscosity of the medicinal composition is prevented. The medicinal composition according to the present invention, which contains ...  
WO/2018/234433A1
A combination comprising a Mcl-1 inhibitor and a second anticancer agent, wherein the second anticancer agent is selected from anthracyclines, cytarabine and hypomethylating agents, and compositions and uses thereof.  
WO/2018/234556A1
The invention relates to methods for preventing or treating resistance to EGFR inhibitors in cancer patients. More particularly, after performing a screen for small molecules potentially capable of countering cancer resistance to EGFR TK...  
WO/2018/235079A1
Cannabidiolic acid esters, compositions comprising them and uses thereof in the treatment of various diseases, conditions and symptoms.  
WO/2018/237379A2
The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine- 1 -phosphate receptor agonists, such as ozanimod.  
WO/2018/234301A1
The present invention relates to compositions comprising Cannabidiol (CBD) or pharmaceutically acceptable salts thereof, and bacitracin or pharmaceutically acceptable salts thereof and/or daptomycin or pharmaceutically acceptable salts t...  
WO/2018/235082A1
The present invention discloses compositions, means and kits thereof for treating neuronal clinical indications in a mammalian subject. The composition comprises, inter alia, a synergistic combination of an anti-inflammatory drug and a D...  
WO/2018/235939A1
The present invention provides an ophthalmic composition and a use thereof. In one embodiment of the present invention, an ophthalmic composition containing a clathrated antioxidant substance is provided. In some of embodiments of the pr...  
WO/2018/236959A1
The disclosure relates to compositions and methods of treating cancer in a subject. The method comprises administering to a patient in need of treatment an effective amount of imipramine.  
WO/2018/233604A1
Provided are an application of a plasminogen to regulate and control the GLP-1/GLP-1R and the treatment of GLP-1/GLP-1R related diseases.  
WO/2018/237326A1
Disclosed herein are compositions and methods for treating cancer in a subject. In some embodiments, the methods involve generating an immune response in an individual by inducing the expression of neoantigens on the surface of abnormal ...  
WO/2018/237041A1
The present disclosure relates to Fibroblast Growth Factor Receptor 2 -specific peptide reagents, methods for detecting epithelial-derived cancer cells such as esophageal, colorectal, gastric, pancreatic or breast carcinoma cells using t...  
WO/2018/235103A1
Disclosed herein are methods for treating cancer in a subject in need thereof by administering an agent or pharmaceutically acceptable derivative thereof, optionally with another agent, induces prostate apoptosis response-4 (Par-4) produ...  

Matches 1 - 50 out of 92,689